JW Bioscience, Early Sepsis Diagnosis Technology Granted European Patent Decision
Proving Patentability in Europe Following the US, Japan, and China
[Asia Economy Reporter Jihee Kim] JW Bioscience has proven the patentability of a core technology that enables early diagnosis of sepsis through a simple blood test, receiving approval from the European Patent Office.
JW Bioscience, a subsidiary of JW Life Science, announced on the 8th that the European Patent Office (EPO) has decided to grant a patent for the core technology that allows early diagnosis of sepsis using the biomarker ‘WRS (tryptophan-tRNA synthetase)’. JW Bioscience plans to complete the final patent acquisition by undergoing individual document procedures targeting major European countries. Currently, it is preparing clinical trials for regulatory approval in collaboration with Sinchon Severance Hospital to develop a sepsis diagnostic kit using WRS, and plans to apply for product approval by the end of this year.
JW Bioscience is the only company globally that holds the core technology patent for WRS, which enables early diagnosis of infectious diseases such as sepsis. Existing sepsis diagnostic markers could only detect infections caused by bacteria, but WRS is also activated by viruses and fungi. Therefore, it is expected to have high diagnostic value not only for bacterial sepsis but also for viral infections such as COVID-19.
A representative from JW Bioscience stated, “We are gaining recognition for our competitiveness by consecutively securing patents for sepsis diagnostic technology using WRS in the global market,” adding, “We will focus the company’s capabilities on addressing unmet medical needs in the global in vitro diagnostics field.”
Hot Picks Today
"Now Our Salaries Are 10 Million Won a Month" Record High... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Wallets Open Wide on Big News...300 Trillion Won Heads to the U.S., "Tax Breaks" Fail to Keep Funds at Home
- "Hope You Enjoy the 'Welfare' for Bereavement of Children"... Ridicule of Strike Non-Participants Intensifies Union Conflict at Samsung Electronics
- "Realizing How Fast Money Disappears: Should You Try Only the Essentials for 5,000 Won? [The Basics of Benefits]"
- Experts Already Watching Closely..."Target Price Set at 970,000 Won" Only Upward Momentum Remains [Weekend Money]
JW Bioscience acquired the WRS core technology from the Medical Bio Convergence Research Group in 2016 and obtained patents starting with Korea in 2017, followed by the United States and Japan last year, and China in August of this year.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
